Lyell Immunopharma Stock Performance
| LYEL Stock | USD 0.92 0.11 10.68% |
The company secures a Beta (Market Risk) of 4.28, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Lyell Immunopharma will likely underperform. At this point, Lyell Immunopharma has a negative expected return of -0.62%. Please make sure to verify Lyell Immunopharma's total risk alpha, as well as the relationship between the kurtosis and day typical price , to decide if Lyell Immunopharma performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Lyell Immunopharma has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unfluctuating performance in the last few months, the Stock's technical and fundamental indicators remain quite persistent which may send shares a bit higher in December 2024. The latest mess may also be a sign of long-standing up-swing for the company institutional investors. ...more
1 | Acquisition by Stephen Hill of 85000 shares of Lyell Immunopharma at 1.87 subject to Rule 16b-3 | 08/30/2024 |
2 | Lyell Immunopharma Announces Participation in Goldman Sachs Cell Therapy Day | 09/24/2024 |
3 | Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its Pipeline to Focus on Next-Generation CAR T-cell Therapies | 10/24/2024 |
4 | Lyell cut to underperform by BofA, pipeline reorganization cited | 10/30/2024 |
5 | LiveOne Leads The Pack Of 3 US Penny Stocks | 11/01/2024 |
6 | Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American So... | 11/05/2024 |
7 | Lyell Immunopharma Upgraded to Buy Heres What You Should Know | 11/14/2024 |
| Begin Period Cash Flow | 123.8 M |
Lyell |
Lyell Immunopharma Relative Risk vs. Return Landscape
If you would invest 159.00 in Lyell Immunopharma on August 24, 2024 and sell it today you would lose (67.00) from holding Lyell Immunopharma or give up 42.14% of portfolio value over 90 days. Lyell Immunopharma is currently does not generate positive expected returns and assumes 7.1201% risk (volatility on return distribution) over the 90 days horizon. In different words, 63% of stocks are less volatile than Lyell, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Lyell Immunopharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Lyell Immunopharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Lyell Immunopharma, and traders can use it to determine the average amount a Lyell Immunopharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.087
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | LYEL |
Estimated Market Risk
| 7.12 actual daily | 63 63% of assets are less volatile |
Expected Return
| -0.62 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.09 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Lyell Immunopharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Lyell Immunopharma by adding Lyell Immunopharma to a well-diversified portfolio.
Lyell Immunopharma Fundamentals Growth
Lyell Stock prices reflect investors' perceptions of the future prospects and financial health of Lyell Immunopharma, and Lyell Immunopharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Lyell Stock performance.
| Return On Equity | -0.33 | ||||
| Return On Asset | -0.19 | ||||
| Current Valuation | (101.51 M) | ||||
| Shares Outstanding | 279.22 M | ||||
| Price To Earning | 3.66 X | ||||
| Price To Book | 0.54 X | ||||
| Price To Sales | 4,565 X | ||||
| Revenue | 130 K | ||||
| Gross Profit | 84.68 M | ||||
| EBITDA | (225.25 M) | ||||
| Net Income | (234.63 M) | ||||
| Cash And Equivalents | 655.56 M | ||||
| Cash Per Share | 2.64 X | ||||
| Total Debt | 63.17 M | ||||
| Debt To Equity | 0.08 % | ||||
| Current Ratio | 13.26 X | ||||
| Book Value Per Share | 2.07 X | ||||
| Cash Flow From Operations | (163.69 M) | ||||
| Earnings Per Share | (0.79) X | ||||
| Market Capitalization | 287.6 M | ||||
| Total Asset | 750.03 M | ||||
| Retained Earnings | (1 B) | ||||
| Working Capital | 520.17 M | ||||
About Lyell Immunopharma Performance
By examining Lyell Immunopharma's fundamental ratios, stakeholders can obtain critical insights into Lyell Immunopharma's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Lyell Immunopharma is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.31) | (0.33) | |
| Return On Capital Employed | (0.34) | (0.36) | |
| Return On Assets | (0.31) | (0.33) | |
| Return On Equity | (0.36) | (0.38) |
Things to note about Lyell Immunopharma performance evaluation
Checking the ongoing alerts about Lyell Immunopharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Lyell Immunopharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Lyell Immunopharma generated a negative expected return over the last 90 days | |
| Lyell Immunopharma has high historical volatility and very poor performance | |
| Lyell Immunopharma has some characteristics of a very speculative penny stock | |
| Lyell Immunopharma has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 130 K. Net Loss for the year was (234.63 M) with profit before overhead, payroll, taxes, and interest of 84.68 M. | |
| Lyell Immunopharma currently holds about 655.56 M in cash with (163.69 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.64, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Lyell Immunopharma has a poor financial position based on the latest SEC disclosures | |
| Roughly 62.0% of the company shares are owned by institutional investors | |
| Latest headline from zacks.com: Lyell Immunopharma Upgraded to Buy Heres What You Should Know |
- Analyzing Lyell Immunopharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Lyell Immunopharma's stock is overvalued or undervalued compared to its peers.
- Examining Lyell Immunopharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Lyell Immunopharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Lyell Immunopharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Lyell Immunopharma's stock. These opinions can provide insight into Lyell Immunopharma's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lyell Immunopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. For more information on how to buy Lyell Stock please use our How to buy in Lyell Stock guide.You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lyell Immunopharma. If investors know Lyell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lyell Immunopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.79) | Quarterly Revenue Growth 0.36 | Return On Assets (0.19) | Return On Equity (0.33) |
The market value of Lyell Immunopharma is measured differently than its book value, which is the value of Lyell that is recorded on the company's balance sheet. Investors also form their own opinion of Lyell Immunopharma's value that differs from its market value or its book value, called intrinsic value, which is Lyell Immunopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lyell Immunopharma's market value can be influenced by many factors that don't directly affect Lyell Immunopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lyell Immunopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lyell Immunopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lyell Immunopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.